Stock listing

NYSE American:IBO Impact BioMedical, Inc. Stock

Home listing (NYSE American) of Impact BioMedical, Inc.

Follow Impact BioMedical, Inc. into a list and get an email when it puts out news.

Share price · AMEX:IBO

$6.17 USD +1.26 (+25.7%)

Close on Nov 17, 2026

Past year +9.2% · daily closes, Nov 17, 2025 – Nov 17, 2026, adjusted for splits
Day range
$5.13 – $6.45 USDNov 17, 2026
Volume
25,481 sharesNov 17, 2026
Market cap
$53.31M USDAt the close on Nov 17, 2026 · price × 8.64M shares outstanding
52-week range
$2.43 – $10.44 USDLowest and highest trades, Nov 18, 2025 – Nov 17, 2026
Traded on an average day
$47,062 USDMedian day 8,189 shares · last 3 months, Aug 17, 2026 – Nov 17, 2026
Impact BioMedical, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:IBO · Home$6.17 USD+1.26 (+25.7%)25,481$5.185$6.45$5.131$4.91Close on Nov 17, 2026

Daily closes

Last 3 months, Aug 17, 2026 – Nov 17, 2026 · AMEX:IBO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$6.17+1.26+25.7%$5.185$6.45$5.13125,481
$4.91-0.23-4.5%$5.13$5.15$4.9012,992
$5.14+0.37+7.8%$4.90$5.177$4.909,860
$4.77+0.47+10.9%$4.59$5.035$4.597,239
$4.30-0.32-6.9%$4.51$4.51$4.301,696
$4.62+0.29+6.7%$4.30$4.62$4.3010,216
$4.33+0.23+5.6%$4.03$4.70$4.014,448
$4.10-0.30-6.8%$4.39$4.39$4.053,255
$4.40+0.30+7.3%$4.10$4.48$4.0014,477
$4.10+0.08+2.0%$4.18$4.525$3.8833,691
$4.02+0.01+0.2%$4.43$4.51$4.0016,743
$4.01+0.21+5.5%$3.80$4.48$3.8020,639
$3.80-0.07-1.8%$3.52$4.10$3.5215,292
$3.87-0.12-3.0%$4.25$4.25$3.7123,862
$3.99+0.44+12.4%$3.40$4.38$3.4039,888
$3.55-0.18-4.8%$3.78$4.11$3.5512,269
$3.73+0.13+3.6%$3.74$3.88$3.1012,613
$3.60-0.20-5.3%$3.69$4.02$3.5411,828
$3.80-0.22-5.5%$3.82$4.23$3.6021,552
$4.02+0.752+23.0%$3.60$4.32$3.6027,680
$3.268+0.208+6.8%$2.78$3.42$2.67412,335
$3.06+0.38+14.2%$2.66$3.75$2.6647,951
$2.68-0.478-15.1%$3.21$3.21$2.4310,214
$3.158-0.245-7.2%$3.17$4.08$2.6229,041
$3.403-0.577-14.5%$3.59$3.85$3.253,967
$3.98-0.05-1.2%$4.11$4.11$3.849,476
$4.03-0.22-5.2%$4.25$4.46$4.007,387
$4.25+0.14+3.4%$4.13$4.39$4.134,028
$4.11-0.37-8.3%$4.32$4.41$4.0617,560
$4.48-0.20-4.3%$4.57$4.59$4.3610,739
$4.68-0.16-3.3%$5.00$5.05$4.4321,172
$4.84-0.48-9.0%$5.16$5.42$4.8417,338
$5.32-0.11-2.0%$5.54$5.54$5.26511,554
$5.43-0.17-3.0%$5.88$5.88$5.438,991
$5.600.000.0%$5.48$5.75$5.483,926
$5.60-0.01-0.2%$5.50$6.17$5.439,044
$5.61-0.08-1.4%$5.69$6.023$5.599,265
$5.69+0.04+0.7%$5.80$6.50$5.5820,645
$5.65-0.98-14.8%$6.86$6.86$5.5123,370
$6.63-0.008-0.1%$6.46$7.11$5.6240,516
$6.638-0.353-5.1%$6.98$6.98$6.638972
$6.991-0.432-5.8%$7.423$7.509$6.921572
$7.423+0.233+3.2%$7.19$7.423$6.921613
$7.19+0.924+14.7%$6.565$7.675$6.5651,604
$6.266-0.39-5.9%$6.795$6.882$6.2661,034
$6.656+0.565+9.3%$6.04$6.906$6.021764
$6.09+0.30+5.2%$5.688$6.516$5.688710
$5.79+0.241+4.3%$5.621$6.165$5.6211,950
$5.549-0.663-10.7%$5.977$6.395$5.4571,711
$6.212-0.08-1.3%$6.405$6.417$6.061309
$6.291-0.504-7.4%$6.417$6.715$6.291948
$6.795+0.755+12.5%$6.04$8.053$5.91425,955
$6.04-0.125-2.0%$6.04$6.152$5.915518
$6.165+0.403+7.0%$5.944$6.165$5.788283
$5.762-0.039-0.7%$6.077$6.165$5.732168
$5.801+0.218+3.9%$5.549$5.92$5.54953
$5.583+0.034+0.6%$5.583$5.788$5.56242
$5.549+0.011+0.2%$5.536$5.794$5.536322
$5.538-0.252-4.4%$5.623$6.136$5.53682
$5.79+0.091+1.6%$5.964$6.152$5.536338
$5.699-0.341-5.6%$5.717$6.01$5.67589
$6.04+0.387+6.9%$5.515$6.04$5.515143
$5.652+0.202+3.7%$5.413$5.772$5.413153
$5.451-0.463-7.8%$5.735$5.824$5.451197
$5.914-0.093-1.6%$5.781$6.005$5.775167
$6.007+0.228+4.0%$5.536$6.027$5.536343

Splits

1 split · AMEX:IBO · every price before a split is adjusted for it

DayRatioWhat
1-for-12.62Consolidation
Ticker
NYSE American:IBO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All Impact BioMedical, Inc. news

Impact BioMedical, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
5 in the last 12 months · 9 in all · newest Nov 3, 2026 · oldest 2024
Decks
3 decks · latest January 2025

Where Impact BioMedical, Inc. is listed

ListingExchangeCountryCurrency
NYSE American:IBO · Home listing · This pageNYSE AmericanUnited StatesUSD
BOATS:IBOBOATSUnited StatesUSD

Valuation

EV/sales 1,402× against a median of 23.6×: the highest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 17, 2026

Enterprise value
$53.29M USD
P/E
33.0×
EV/sales
1,402×
EV/EBITDA
Negative EBITDA
Price/book
5.3×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
0.06

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Impact BioMedical, Inc. · AMEX:IBOUS$53.31MUS$53.29M33.0×1,402×n/a5.3×n/a0.0×0.06
EyeGene, Inc. · KRX:185490US$55.23MUS$26.50Mn/a8.0×n/a1.5×−391.5%0.0×n/a
AB Science SA · EURONEXT:ABUS$55.19MUS$50.54Mn/a39.2×n/an/a−132.6%n/an/a
Azora Therapeutics, Inc. · NASDAQ:AZRUS$55.00MUS$33.00Mn/an/an/an/an/an/a1.00
Island Pharmaceuticals Ltd · ASX:ILAUS$54.84MUS$46.32Mn/a248×n/a6.2×n/a0.0×n/a
Anavex Life Sciences Corp. · NASDAQ:AVXLUS$54.83M−US$63.50Mn/an/an/a0.5×n/a0.0×2.39
Nordicus Partners Corp · OTC:NORDUS$54.44MUS$54.44Mn/an/an/a0.9×n/a0.0×0.45
Boundless Bio, Inc. · NASDAQ:BOLDUS$53.61M−US$9.28Mn/an/an/a0.9×n/a0.0×0.65
Xilio Therapeutics, Inc. · NASDAQ:XLOUS$53.40M−US$62.82Mn/a−1.1×n/a0.8×−20.9%0.1×0.76
XBiotech Inc. · NASDAQ:XBITUS$52.74M−US$52.29Mn/an/an/a0.4×n/a0.0×0.52
Bonus Biogroup Ltd. · TASE:BONSUS$52.22MUS$54.52Mn/an/an/an/an/an/an/a
Median of the othersUS$54.64MUS$29.75M23.6×0.9×−132.6%0.0×0.71

Team and board

Officers

OfficerRole
Frank D. HeuszelChief Executive Officer
Todd MackoChief Financial Officer
Mark SuseckChief Operating Officer

Board

DirectorRole
Frank D. HeuszelChief Executive Officer
Ambrose Chan Heng Fai
Castel Hibbert
Chris Zimmerman
David Keene
Elise Brownell
Jason Grady
Melissa Sims

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026+12.7%
Q2 2026Aug 7, 2026−3.4%
Q3 2025Nov 7, 2025+4.8%
Q2 2025Aug 14, 2025+5.0%
Q1 2025May 14, 2025−6.4%
Q4 2024Mar 28, 2025−61.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (January 2025)Investor deck19 slidesJanuary 2025
Investor Presentation (November 2024)Investor deck10 slidesNov 4, 2024
Investor Presentation (August 2024)Investor deck16 slidesAugust 2024

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue32.0K1.62M1.03M50.0K50.0K0
Cost of revenue424.0K1.12M1.12M1.11M1.11M
Gross profit-392.0K1.62M-1.12M50.0K50.0K
Research and development340.0K278.0K1.69M1.23M1.23M513.7K442.3K
Selling, general and administrative873.0K718.0K315.0K325.0K1.05M383.4K237.7K68.8K176.2K
Operating income-4.28M-28.8M-4.03M-3.40M-3.40M-896.7K-680.0K-33.9K64.0K
Depreciation and amortization1.15M1.12M1.12M1.11M1.11M1.14M255171.9K161.1K
EBITDA-3.14M-27.6M-2.91M-2.29M-2.29M244.3K-679.8K138.0K225.1K
Interest expense793.0K1.06M444.0K462.0K300.0K
Income before tax-14.4M-24.7M-4.41M-7.88M-7.88M-896.7K-849.2K-98.1K-408.3K
Income tax-2.58M33.0K-621.0K-621.0K-82.0K59.1K
Net income-11.8M-24.7M-4.34M-7.25M-7.05M-597.3K-590.1K-98.1K-408.3K
Earnings per share, basic-0.38-2.30-0.07-0.10-7.74-0.66-0.05-0.01-0.04
Earnings per share, diluted-0.38-2.30-0.07-0.10

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.00K2.00M1.00K2.00K46.0K72.3K97.7K204.9K51.9K387.8K
Short-term investments2.00M
Receivables5.00K201.0K016.0K197.0K14.1K35.2K4.38K28.6K850
Inventory63.0K-265
Current assets411.0K2.45M332.0K122.0K287.0K107.3K115.3K217.2K320.7K405.6K
Property, plant and equipment017.0K287.0K276.0K
Goodwill25.1M25.1M25.1M25.1M25.1M
Total assets17.4M20.3M44.6M46.5M56.4M48.1M116.6K217.2K320.7K405.6K
Accounts payable347.0K314.0K832.0K539.0K115.0K9.27K
Current liabilities1.16M9.79M13.1M10.6M12.6M1.07M21.7K20.1K25.4K5.60K
Total debt8.88M12.1M9.99M12.5M1.06M
Total liabilities1.85M13.1M16.4M13.8M16.5M6.32M21.7K20.1K25.4K5.60K
Shareholders' equity12.3M4.26M25.2M29.6M36.6M37.9M94.9K197.1K295.2K400.0K
Shares outstanding8.29M11.5M10.0M70.5M911.6K911.6K11.8M9.81M10.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-1.89M-2.85M-2.85M-2.24M-2.24M-898.5K-122.0K-72.0K-320.3K
Capital spending00-18.0K-276.0K-276.0K-3-1.53K00
Free cash flow-1.89M-5.64M-2.87M-2.52M-2.52M-898.5K-123.5K-72.0K-320.3K
Cash from investing3.00K2.00K-15.0K-349.0K-349.0K-632.1K-26.5K225.0K-225.0K
Cash from financing-109.0K4.85M2.87M2.55M2.55M1.49M16.1K209.5K
Dividends paid-410.0K-410.0K
Share buybacks3.73M-46.5K-46.5K
Change in cash-2.00M2.00M-1.00K-44.0K-44.0K72.3K-132.4K153.0K-335.8K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 18, 2026Acquisition or disposalSEC
25-NSENov 18, 2026Other filingsSEC
8-K · Current reportNov 17, 2026Meeting outcomeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
All 159 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
8-K · Current reportNov 3, 2026Current reportSEC
425Nov 3, 2026Other filingsSEC
DEFM14AOct 26, 2026Meeting noticeSEC
8-K · Current reportOct 9, 2026Current reportSEC
4 · Change in ownershipSep 24, 2026Insider tradeSEC
425Sep 16, 2026Other filingsSEC
8-K · Current reportSep 16, 2026Current reportSEC
425Sep 14, 2026Other filingsSEC
8-K · Current reportSep 14, 2026Current reportSEC
10-Q · Quarterly reportAug 7, 2026Quarterly reportSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
144 · Notice of proposed saleApr 29, 2026Other filingsSEC
S-8 POSApr 22, 2026Offer documentSEC
S-8 POSApr 6, 2026Offer documentSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
10-K · Annual reportMar 11, 2026Annual reportSEC
8-K · Current reportMar 4, 2026Material contractSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
DEF 14CDec 30, 2025Meeting noticeSEC
PRE 14CDec 11, 2025Meeting noticeSEC
10-Q · Quarterly reportNov 7, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025Meeting outcomeSEC
8-K · Current reportOct 27, 2025Current reportSEC
DEF 14A · Proxy statementSep 22, 2025Meeting noticeSEC
DEF 14CSep 9, 2025Meeting noticeSEC
PRE 14CAug 26, 2025Meeting noticeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
DEF 14CAug 5, 2025Meeting noticeSEC
8-K · Current reportJul 28, 2025Material contractSEC
PRE 14CJul 16, 2025Meeting noticeSEC
8-K · Current reportJun 23, 2025Material contractSEC
4 · Change in ownershipMay 27, 2025Insider tradeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 4, 2025Big-stake noticeSEC
8-K · Current reportApr 3, 2025Material contractSEC
SCHEDULE 13D · Big-stake noticeApr 2, 2025Big-stake noticeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
10-K · Annual reportMar 28, 2025Annual reportSEC
8-K · Current reportMar 28, 2025Material contractSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
8-K · Current reportMar 13, 2025Management or board changeSEC
UPLOAD · Letter from the SECMar 10, 2025Other filingsSEC
CORRESP · Letter to the SECMar 7, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 6, 2025Other filingsSEC
8-K · Current reportJan 29, 2025Current reportSEC
S-8 · Registration statement for employee plansJan 24, 2025Offer documentSEC
CORRESP · Letter to the SECJan 10, 2025Other filingsSEC
UPLOAD · Letter from the SECDec 20, 2024Other filingsSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 4, 2024Current reportSEC
8-K · Current reportOct 8, 2024Management or board changeSEC
4 · Change in ownershipSep 19, 2024Insider tradeSEC
4 · Change in ownershipSep 18, 2024Insider tradeSEC
3/A · Initial statement of ownership, amendedSep 18, 2024Insider tradeSEC
8-K · Current reportSep 17, 2024Material contractSEC
3 · Initial statement of ownershipSep 17, 2024Insider tradeSEC
424B4 · ProspectusSep 17, 2024Offer documentSEC
3 · Initial statement of ownershipSep 16, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveSep 16, 2024Other filingsSEC
CORRESP · Letter to the SECSep 9, 2024Other filingsSEC
CORRESP · Letter to the SECSep 9, 2024Other filingsSEC
CORRESP · Letter to the SECSep 5, 2024Other filingsSEC
CORRESP · Letter to the SECSep 5, 2024Other filingsSEC
CORRESP · Letter to the SECSep 3, 2024Other filingsSEC
CORRESP · Letter to the SECSep 3, 2024Other filingsSEC
S-1/A · Registration statement, amendedAug 27, 2024Offer documentSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedAug 23, 2024Other filingsSEC
S-1/A · Registration statement, amendedAug 20, 2024Offer documentSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
CORRESP · Letter to the SECAug 12, 2024Other filingsSEC
CORRESP · Letter to the SECAug 12, 2024Other filingsSEC
S-1/A · Registration statement, amendedAug 9, 2024Offer documentSEC
CERT · Exchange's certificate of listingAug 9, 2024Other filingsSEC
CORRESP · Letter to the SECAug 8, 2024Other filingsSEC
CORRESP · Letter to the SECAug 8, 2024Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeAug 8, 2024Other filingsSEC
S-1/A · Registration statement, amendedJun 11, 2024Offer documentSEC
8-K · Current reportJun 7, 2024Management or board changeSEC
10-Q · Quarterly reportMay 10, 2024Quarterly reportSEC
S-1/A · Registration statement, amendedFeb 28, 2024Offer documentSEC
10-K · Annual reportFeb 20, 2024Annual reportSEC
8-K · Current reportJan 22, 2024Material contractSEC
S-1/A · Registration statement, amendedNov 21, 2023Offer documentSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 6, 2023Material contractSEC
S-1/A · Registration statement, amendedNov 1, 2023Offer documentSEC
UPLOAD · Letter from the SECOct 25, 2023Other filingsSEC
S-1 · Registration statementOct 17, 2023Offer documentSEC
10-Q · Quarterly reportOct 5, 2023Quarterly reportSEC
EFFECT · Notice that a registration is effectiveAug 7, 2023Other filingsSEC
CORRESP · Letter to the SECAug 2, 2023Other filingsSEC
S-1/A · Registration statement, amendedAug 1, 2023Offer documentSEC
CORRESP · Letter to the SECJul 24, 2023Other filingsSEC
S-1/A · Registration statement, amendedJul 24, 2023Offer documentSEC
UPLOAD · Letter from the SECJul 13, 2023Other filingsSEC
CORRESP · Letter to the SECJun 30, 2023Other filingsSEC
S-1/A · Registration statement, amendedJun 30, 2023Offer documentSEC
UPLOAD · Letter from the SECJun 27, 2023Other filingsSEC
CORRESP · Letter to the SECJun 21, 2023Other filingsSEC
S-1/A · Registration statement, amendedJun 21, 2023Offer documentSEC
UPLOAD · Letter from the SECJun 9, 2023Other filingsSEC
S-1/A · Registration statement, amendedJun 2, 2023Offer documentSEC
CORRESP · Letter to the SECJun 2, 2023Other filingsSEC
UPLOAD · Letter from the SECMay 25, 2023Other filingsSEC
S-1/A · Registration statement, amendedMay 15, 2023Offer documentSEC
CORRESP · Letter to the SECJan 31, 2023Other filingsSEC
S-1/A · Registration statement, amendedJan 31, 2023Offer documentSEC
UPLOAD · Letter from the SECJan 20, 2023Other filingsSEC
CORRESP · Letter to the SECJan 9, 2023Other filingsSEC
S-1/A · Registration statement, amendedJan 9, 2023Offer documentSEC
UPLOAD · Letter from the SECJan 3, 2023Other filingsSEC
CORRESP · Letter to the SECDec 7, 2022Other filingsSEC
S-1/A · Registration statement, amendedDec 7, 2022Offer documentSEC
UPLOAD · Letter from the SECAug 31, 2022Other filingsSEC
CORRESP · Letter to the SECAug 24, 2022Other filingsSEC
S-1/A · Registration statement, amendedAug 24, 2022Offer documentSEC
UPLOAD · Letter from the SECAug 11, 2022Other filingsSEC
S-1/A · Registration statement, amendedAug 2, 2022Offer documentSEC
CORRESP · Letter to the SECAug 2, 2022Other filingsSEC
UPLOAD · Letter from the SECJul 21, 2022Other filingsSEC
S-1/A · Registration statement, amendedJul 11, 2022Offer documentSEC
S-1/A · Registration statement, amendedJun 24, 2022Offer documentSEC
CORRESP · Letter to the SECJun 24, 2022Other filingsSEC
UPLOAD · Letter from the SECOct 26, 2021Other filingsSEC
CORRESP · Letter to the SECSep 29, 2021Other filingsSEC
S-1/A · Registration statement, amendedSep 29, 2021Offer documentSEC
UPLOAD · Letter from the SECFeb 24, 2021Other filingsSEC
S-1 · Registration statementFeb 12, 2021Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Impact BioMedical, Inc.’s releases · as of Nov 5, 2026

Common shares
8,640,000
Fully diluted
8,640,000

Fully diluted

LineSharesAs of
Common shares8,640,000Nov 5, 2026

Share count over time

CountShares
Nov 5, 20268,640,000
Sep 14, 2026
Sep 11, 2026

Open Cap table

Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund785K9.1%US$361KJun 30, 2026
Fidelity Extended Market Index Fund567K6.6%US$295KMay 31, 2026
Fidelity Total Market Index Fund237K2.7%US$123KMay 31, 2026
Fidelity Series Total Market Index Fund155K1.8%US$80,571May 31, 2026
Total Stock Market Index Trust2,2740.03%US$1,046Jun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF6<0.01%US$3Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Dss, Inc.
10% owner
Sale156USD 7.06US$1,101Sep 24, 2026
Dss, Inc.
10% owner
Sale27USD 6.95US$188Sep 23, 2026
Dss, Inc.
10% owner
Sale723USD 0.55US$398Sep 22, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Heng Fai Ambrose Chan
Other companies: HWH International Inc. (Chief Executive Officer, Director · Since at least Jan 9, 2024); Alset Inc. (Chief Executive Officer, Director · Since at least Nov 23, 2020); DSS, Inc. (Director · Since at least Jan 12, 2017); Value Exchange International, Inc. (Director · Oct 3, 2022 – Mar 28, 2025 · Past); Sharing Services Global Corp. (Director · Apr 30, 2020 – Mar 31, 2025 · Past); OptimumBank Holdings, Inc. (Director · Jun 26, 2018 – Jul 23, 2021 · Past); Chiron Real Estate Inc. (Director · Apr 14, 2014 – Apr 14, 2014 · Past)
Director · Since at least Mar 31, 2025
Ambrose Chan Heng Fai
Other companies: DSS, Inc. (Executive Chairman, Director · Since at least Nov 5, 2026)
Director · Since at least Nov 5, 2026
Jason T. Grady
Other companies: DSS, Inc. (Interim CEO · Since at least Jul 11, 2019)
Director · Since at least Sep 16, 2024
Todd D. Macko
Other companies: DSS, Inc. (CFO · Since at least Oct 28, 2020)
Chief Financial Officer · Since at least Sep 16, 2024
Castel HibbertDirector · Since at least Oct 7, 2026
Christian Thomas ZimmermanDirector · Since at least Sep 16, 2024
Chris ZimmermanDirector · Since at least Nov 4, 2026
David KeeneDirector · Since at least Sep 16, 2024
Elise BrownellDirector · Since at least Sep 16, 2024
Frank D. HeuszelChief Executive Officer · Since at least Nov 3, 2026
All 12 people
PersonSeat
Mark SuseckChief Operating Officer · Since at least Sep 16, 2024
Melissa SimsDirector · Since at least Sep 16, 2024

Open People

Log in to ask 6ix AI your own questions about Impact BioMedical, Inc.